 | • レポートコード：MMG23DC12238 • 出版社/出版日：Market Monitor Global / 2023年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、103ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User（1名様閲覧用） | ￥471,250 (USD3,250) | ▷ お問い合わせ |
| Multi User（20名様閲覧用） | ￥612,625 (USD4,225) | ▷ お問い合わせ |
| Enterprise User（閲覧人数制限なし） | ￥706,875 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の同種幹細胞移植市場規模と予測を収録しています。・世界の同種幹細胞移植市場：売上、2018年-2023年、2024年-2029年 ・世界の同種幹細胞移植市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の同種幹細胞移植市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「非改変幹細胞移植」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 同種幹細胞移植のグローバル主要企業は、Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plcなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、同種幹細胞移植のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の同種幹細胞移植市場：タイプ別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：タイプ別市場シェア、2022年 ・非改変幹細胞移植、T細胞除去移植、臍帯血移植、ドナーリンパ球注入 世界の同種幹細胞移植市場：用途別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：用途別市場シェア、2022年 ・病院、外来手術センター、その他 世界の同種幹細胞移植市場：地域・国別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における同種幹細胞移植のグローバル売上、2018年-2023年 ・主要企業における同種幹細胞移植のグローバル売上シェア、2022年 ・主要企業における同種幹細胞移植のグローバル販売量、2018年-2023年 ・主要企業における同種幹細胞移植のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plc ************************************************************* ・調査・分析レポートの概要 同種幹細胞移植市場の定義 市場セグメント 世界の同種幹細胞移植市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の同種幹細胞移植市場規模 世界の同種幹細胞移植市場規模：2022年 VS 2029年 世界の同種幹細胞移植市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの同種幹細胞移植の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の同種幹細胞移植製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：非改変幹細胞移植、T細胞除去移植、臍帯血移植、ドナーリンパ球注入 同種幹細胞移植のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、外来手術センター、その他 同種幹細胞移植の用途別グローバル売上・予測 ・地域別市場分析 地域別同種幹細胞移植市場規模 2022年と2029年 地域別同種幹細胞移植売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plc ... |
This research report provides a comprehensive analysis of the Allogeneic Stem Cell Transplantation market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Allogeneic Stem Cell Transplantation market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Allogeneic Stem Cell Transplantation, challenges faced by the industry, and potential opportunities for market players.
The global Allogeneic Stem Cell Transplantation market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Allogeneic Stem Cell Transplantation market presents opportunities for various stakeholders, including Hospital, Ambulatory Surgical Center. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Allogeneic Stem Cell Transplantation market. Additionally, the growing consumer demand present avenues for market expansion.
The global Allogeneic Stem Cell Transplantation market was valued at US$ 943.2 million in 2022 and is projected to reach US$ 1443.8 million by 2029, at a CAGR of 6.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Allogeneic Stem Cell Transplantation market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Allogeneic Stem Cell Transplantation market.
Market Overview: The report provides a comprehensive overview of the Allogeneic Stem Cell Transplantation market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Unmodified Stem Cell Transplant, T-cell Depleted Transplant), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Allogeneic Stem Cell Transplantation market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Allogeneic Stem Cell Transplantation market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Allogeneic Stem Cell Transplantation market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Allogeneic Stem Cell Transplantation market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Allogeneic Stem Cell Transplantation market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Allogeneic Stem Cell Transplantation market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Allogeneic Stem Cell Transplantation, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Allogeneic Stem Cell Transplantation market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Allogeneic Stem Cell Transplantation market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Market segment by Application
Hospital
Ambulatory Surgical Center
Others
Global Allogeneic Stem Cell Transplantation Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Allogeneic Stem Cell Transplantation, market overview.
Chapter 2: Global Allogeneic Stem Cell Transplantation market size in revenue.
Chapter 3: Detailed analysis of Allogeneic Stem Cell Transplantation company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Allogeneic Stem Cell Transplantation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Allogeneic Stem Cell Transplantation Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Allogeneic Stem Cell Transplantation Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Allogeneic Stem Cell Transplantation Overall Market Size
2.1 Global Allogeneic Stem Cell Transplantation Market Size: 2022 VS 2029
2.2 Global Allogeneic Stem Cell Transplantation Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Allogeneic Stem Cell Transplantation Players in Global Market
3.2 Top Global Allogeneic Stem Cell Transplantation Companies Ranked by Revenue
3.3 Global Allogeneic Stem Cell Transplantation Revenue by Companies
3.4 Top 3 and Top 5 Allogeneic Stem Cell Transplantation Companies in Global Market, by Revenue in 2022
3.5 Global Companies Allogeneic Stem Cell Transplantation Product Type
3.6 Tier 1, Tier 2 and Tier 3 Allogeneic Stem Cell Transplantation Players in Global Market
3.6.1 List of Global Tier 1 Allogeneic Stem Cell Transplantation Companies
3.6.2 List of Global Tier 2 and Tier 3 Allogeneic Stem Cell Transplantation Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Allogeneic Stem Cell Transplantation Market Size Markets, 2022 & 2029
4.1.2 Unmodified Stem Cell Transplant
4.1.3 T-cell Depleted Transplant
4.1.4 Cord Blood Transplant
4.1.5 Donor Lymphocyte Infusion
4.2 By Type – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
4.2.1 By Type – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
4.2.2 By Type – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
4.2.3 By Type – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Allogeneic Stem Cell Transplantation Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Ambulatory Surgical Center
5.1.4 Others
5.2 By Application – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
5.2.1 By Application – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
5.2.2 By Application – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
5.2.3 By Application – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Allogeneic Stem Cell Transplantation Market Size, 2022 & 2029
6.2 By Region – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
6.2.1 By Region – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
6.2.2 By Region – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
6.2.3 By Region – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.3.2 US Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.3.3 Canada Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.3.4 Mexico Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.4.2 Germany Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.3 France Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.4 U.K. Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.5 Italy Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.6 Russia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.7 Nordic Countries Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.8 Benelux Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.5.2 China Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.3 Japan Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.4 South Korea Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.5 Southeast Asia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.6 India Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.6.2 Brazil Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.6.3 Argentina Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.7.2 Turkey Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.3 Israel Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.4 Saudi Arabia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.5 UAE Allogeneic Stem Cell Transplantation Market Size, 2018-2029
7 Allogeneic Stem Cell Transplantation Companies Profiles
7.1 Mesoblast Limited
7.1.1 Mesoblast Limited Company Summary
7.1.2 Mesoblast Limited Business Overview
7.1.3 Mesoblast Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.1.4 Mesoblast Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.1.5 Mesoblast Limited Key News & Latest Developments
7.2 Gamida Cell Ltd.
7.2.1 Gamida Cell Ltd. Company Summary
7.2.2 Gamida Cell Ltd. Business Overview
7.2.3 Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Major Product Offerings
7.2.4 Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.2.5 Gamida Cell Ltd. Key News & Latest Developments
7.3 Novartis International AG
7.3.1 Novartis International AG Company Summary
7.3.2 Novartis International AG Business Overview
7.3.3 Novartis International AG Allogeneic Stem Cell Transplantation Major Product Offerings
7.3.4 Novartis International AG Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.3.5 Novartis International AG Key News & Latest Developments
7.4 Cellectis SA
7.4.1 Cellectis SA Company Summary
7.4.2 Cellectis SA Business Overview
7.4.3 Cellectis SA Allogeneic Stem Cell Transplantation Major Product Offerings
7.4.4 Cellectis SA Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.4.5 Cellectis SA Key News & Latest Developments
7.5 Magenta Therapeutics Inc.
7.5.1 Magenta Therapeutics Inc. Company Summary
7.5.2 Magenta Therapeutics Inc. Business Overview
7.5.3 Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.5.4 Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.5.5 Magenta Therapeutics Inc. Key News & Latest Developments
7.6 Fate Therapeutics Inc.
7.6.1 Fate Therapeutics Inc. Company Summary
7.6.2 Fate Therapeutics Inc. Business Overview
7.6.3 Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.6.4 Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.6.5 Fate Therapeutics Inc. Key News & Latest Developments
7.7 Cynata Therapeutics Limited
7.7.1 Cynata Therapeutics Limited Company Summary
7.7.2 Cynata Therapeutics Limited Business Overview
7.7.3 Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.7.4 Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.7.5 Cynata Therapeutics Limited Key News & Latest Developments
7.8 Kiadis Pharma N.V
7.8.1 Kiadis Pharma N.V Company Summary
7.8.2 Kiadis Pharma N.V Business Overview
7.8.3 Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Major Product Offerings
7.8.4 Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.8.5 Kiadis Pharma N.V Key News & Latest Developments
7.9 Takeda Pharmaceutical Company Limited
7.9.1 Takeda Pharmaceutical Company Limited Company Summary
7.9.2 Takeda Pharmaceutical Company Limited Business Overview
7.9.3 Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.9.4 Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.9.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.10 JCR Pharmaceuticals Co., Ltd.
7.10.1 JCR Pharmaceuticals Co., Ltd. Company Summary
7.10.2 JCR Pharmaceuticals Co., Ltd. Business Overview
7.10.3 JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Major Product Offerings
7.10.4 JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.10.5 JCR Pharmaceuticals Co., Ltd. Key News & Latest Developments
7.11 Pluristem Therapeutics Inc.
7.11.1 Pluristem Therapeutics Inc. Company Summary
7.11.2 Pluristem Therapeutics Inc. Business Overview
7.11.3 Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.11.4 Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.11.5 Pluristem Therapeutics Inc. Key News & Latest Developments
7.12 Celularity Inc.
7.12.1 Celularity Inc. Company Summary
7.12.2 Celularity Inc. Business Overview
7.12.3 Celularity Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.12.4 Celularity Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.12.5 Celularity Inc. Key News & Latest Developments
7.13 Lineage Cell Therapeutics Inc.
7.13.1 Lineage Cell Therapeutics Inc. Company Summary
7.13.2 Lineage Cell Therapeutics Inc. Business Overview
7.13.3 Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.13.4 Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.13.5 Lineage Cell Therapeutics Inc. Key News & Latest Developments
7.14 Nohla Therapeutics Inc.
7.14.1 Nohla Therapeutics Inc. Company Summary
7.14.2 Nohla Therapeutics Inc. Business Overview
7.14.3 Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.14.4 Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.14.5 Nohla Therapeutics Inc. Key News & Latest Developments
7.15 Orchard Therapeutics Plc
7.15.1 Orchard Therapeutics Plc Company Summary
7.15.2 Orchard Therapeutics Plc Business Overview
7.15.3 Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Major Product Offerings
7.15.4 Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.15.5 Orchard Therapeutics Plc Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Allogeneic Stem Cell Transplantation Market Opportunities & Trends in Global Market
Table 2. Allogeneic Stem Cell Transplantation Market Drivers in Global Market
Table 3. Allogeneic Stem Cell Transplantation Market Restraints in Global Market
Table 4. Key Players of Allogeneic Stem Cell Transplantation in Global Market
Table 5. Top Allogeneic Stem Cell Transplantation Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Allogeneic Stem Cell Transplantation Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Allogeneic Stem Cell Transplantation Revenue Share by Companies, 2018-2023
Table 8. Global Companies Allogeneic Stem Cell Transplantation Product Type
Table 9. List of Global Tier 1 Allogeneic Stem Cell Transplantation Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Allogeneic Stem Cell Transplantation Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Allogeneic Stem Cell Transplantation Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Allogeneic Stem Cell Transplantation Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Allogeneic Stem Cell Transplantation Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Allogeneic Stem Cell Transplantation Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Allogeneic Stem Cell Transplantation Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Allogeneic Stem Cell Transplantation Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2024-2029
Table 30. Mesoblast Limited Company Summary
Table 31. Mesoblast Limited Allogeneic Stem Cell Transplantation Product Offerings
Table 32. Mesoblast Limited Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 33. Mesoblast Limited Key News & Latest Developments
Table 34. Gamida Cell Ltd. Company Summary
Table 35. Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Product Offerings
Table 36. Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 37. Gamida Cell Ltd. Key News & Latest Developments
Table 38. Novartis International AG Company Summary
Table 39. Novartis International AG Allogeneic Stem Cell Transplantation Product Offerings
Table 40. Novartis International AG Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis International AG Key News & Latest Developments
Table 42. Cellectis SA Company Summary
Table 43. Cellectis SA Allogeneic Stem Cell Transplantation Product Offerings
Table 44. Cellectis SA Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 45. Cellectis SA Key News & Latest Developments
Table 46. Magenta Therapeutics Inc. Company Summary
Table 47. Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 48. Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 49. Magenta Therapeutics Inc. Key News & Latest Developments
Table 50. Fate Therapeutics Inc. Company Summary
Table 51. Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 52. Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 53. Fate Therapeutics Inc. Key News & Latest Developments
Table 54. Cynata Therapeutics Limited Company Summary
Table 55. Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Product Offerings
Table 56. Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 57. Cynata Therapeutics Limited Key News & Latest Developments
Table 58. Kiadis Pharma N.V Company Summary
Table 59. Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Product Offerings
Table 60. Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 61. Kiadis Pharma N.V Key News & Latest Developments
Table 62. Takeda Pharmaceutical Company Limited Company Summary
Table 63. Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Product Offerings
Table 64. Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 65. Takeda Pharmaceutical Company Limited Key News & Latest Developments
Table 66. JCR Pharmaceuticals Co., Ltd. Company Summary
Table 67. JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Product Offerings
Table 68. JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 69. JCR Pharmaceuticals Co., Ltd. Key News & Latest Developments
Table 70. Pluristem Therapeutics Inc. Company Summary
Table 71. Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 72. Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 73. Pluristem Therapeutics Inc. Key News & Latest Developments
Table 74. Celularity Inc. Company Summary
Table 75. Celularity Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 76. Celularity Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 77. Celularity Inc. Key News & Latest Developments
Table 78. Lineage Cell Therapeutics Inc. Company Summary
Table 79. Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 80. Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 81. Lineage Cell Therapeutics Inc. Key News & Latest Developments
Table 82. Nohla Therapeutics Inc. Company Summary
Table 83. Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Product Offerings
Table 84. Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 85. Nohla Therapeutics Inc. Key News & Latest Developments
Table 86. Orchard Therapeutics Plc Company Summary
Table 87. Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Product Offerings
Table 88. Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Revenue (US$, Mn) & (2018-2023)
Table 89. Orchard Therapeutics Plc Key News & Latest Developments
List of Figures
Figure 1. Allogeneic Stem Cell Transplantation Segment by Type in 2022
Figure 2. Allogeneic Stem Cell Transplantation Segment by Application in 2022
Figure 3. Global Allogeneic Stem Cell Transplantation Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Allogeneic Stem Cell Transplantation Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Allogeneic Stem Cell Transplantation Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Allogeneic Stem Cell Transplantation Revenue in 2022
Figure 8. By Type - Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 9. By Application - Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 10. By Type - Global Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 12. By Application - Global Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 14. By Region - Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 15. By Country - North America Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 16. US Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 20. Germany Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 21. France Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 28. China Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 32. India Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 34. Brazil Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
Figure 37. Turkey Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Allogeneic Stem Cell Transplantation Revenue, (US$, Mn), 2018-2029
Figure 41. Mesoblast Limited Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis International AG Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Cellectis SA Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Celularity Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
| 【同種幹細胞移植について】 同種幹細胞移植は、患者に健康な幹細胞を供給するために、他の人から採取された幹細胞を使用する医療手法です。この手法は主に、血液の病気や一部のがん、遺伝性疾患の治療に利用されています。以下に、その定義、特徴、種類、用途、関連技術について詳しく説明いたします。 同種幹細胞移植とは、他のドナーから採取された造血幹細胞を使用して、患者の造血系を再生させる治療法です。造血幹細胞は、血液細胞を生成するための基になる細胞であり、白血球、赤血球、血小板などを生み出す役割を担っています。主に末梢血、骨髄、またはへその緒から採取されます。移植は、通常、患者が重篤な病状にある時に行われます。 同種幹細胞移植の最も大きな特徴は、提供される幹細胞が患者自身の細胞ではなく、他の個体から得られることである点です。これにより、患者が自身の病気によって損傷した造血系を再生するための新たな細胞供給源が得られるのです。ただし、ドナーとの細胞の適合性が重要で、HLA（ヒト白血球抗原）型が一致することが理想とされます。適合性が高いほど、移植後の拒絶反応や合併症のリスクが低くなります。 同種幹細胞移植には大きく分けて二つの種類があります。一つ目は、非血縁者からの移植であり、骨髄バンクや幹細胞バンクを通じて不特定のドナーから提供される場合です。この方法では、広範なドナー登録が必要であり、適合するドナーを見つけることが重要な課題となります。二つ目は、血縁者からの移植で、特に兄弟姉妹などが適合している場合に行われます。血縁者からの提供は、細胞の適合性が高い可能性があるため、移植の成功率が比較的高いとされています。 同種幹細胞移植の主な用途は、白血病、リンパ腫、骨髄異形成症候群、サラセミア、先天性免疫不全症などの血液疾患の治療です。また、いくつかの遺伝性疾患や、急性および慢性の血液系の悪性腫瘍にも適用されることがあります。治疗の目的は、病気の根本的な治療および体の造血能力の回復を図ることです。 関連技術としては、HLA型の検査や交差試験、そして移植前後のモニタリング技術があります。特にHLA型の一致を確認することは、同種幹細胞移植の成功に大きく寄与します。さらに、移植後の合併症を減少させるための新しい抗排斥療法や、移植後の回復を促進するための管理技術の進歩も重要な要素です。 また、移植における新たなアプローチとして、幹細胞の操作技術や遺伝子治療が挙げられます。幹細胞を遺伝子操作することにより、特定の疾患に対する抵抗力を高めたり、治療効果を向上させたりすることが期待されています。 ただし、同種幹細胞移植にはリスクが伴います。拒絶反応や移植片対宿主病（GVHD）などの合併症が発生する可能性があり、これが治療の難しさを増しています。GVHDは、移植された細胞が患者の体に対して免疫反応を示すことで起こり、さまざまな臓器に影響を及ぼすことがあります。このため、移植後は厳重な管理とフォローアップが必要です。 今後の研究では、細胞の適合性をより高めるための方法や、合併症を減少させるための新たな治療法の開発が期待されています。さらに、再生医療の分野では、同種幹細胞移植に代わる新しい手法が模索されており、ナノ技術や細胞工学の進展も重要な役割を果たすでしょう。 以上のように、同種幹細胞移植は多くの可能性を秘めていますが、課題も多く残されています。今後の技術革新や研究によって、より多くの患者に希望をもたらす治療法として発展していくことが期待されています。 |
